Long COVID Treatment in 2025: What the Clinical Trials Have Found

Long COVID has been one of the most intensively studied conditions of the past four years, with hundreds of clinical trials launched worldwide. As of 2025, the landscape of evidence-based treatment is beginning to take shape — though it remains incomplete. This article summarizes the most significant trial results and what they mean for patients seeking treatment today.

The Challenge of Treating a Heterogeneous Condition

One of the central difficulties in Long COVID research is that "Long COVID" is not a single disease. It is an umbrella term for a constellation of post-acute sequelae that appear to have multiple distinct biological mechanisms — viral persistence, immune dysregulation, microbiome disruption, autonomic nervous system dysfunction, endothelial damage, and microclotting, among others.

This heterogeneity means that no single treatment is likely to work for all Long COVID patients, and trials that do not stratify patients by mechanism or symptom subtype are likely to show diluted effects. The field is increasingly moving toward precision medicine approaches that match treatment to underlying biology.

Antiviral Approaches

Paxlovid (Nirmatrelvir-Ritonavir)

The RECOVER-VITAL trial, funded by the NIH, tested a 15-day course of Paxlovid (the standard COVID treatment) in Long COVID patients. The hypothesis was that viral persistence — residual SARS-CoV-2 RNA or protein in tissues — might be driving ongoing symptoms.

The trial results were mixed. The 15-day course did not show a statistically significant benefit over placebo on the primary outcome (a composite Long COVID symptom score). However, subgroup analyses suggested possible benefit in patients with specific symptom profiles, and some researchers have argued that longer treatment courses may be needed.

A follow-up trial testing longer Paxlovid courses is ongoing. The current evidence does not support routine use of Paxlovid for Long COVID outside of clinical trials.

Antivirals for EBV and Other Herpesviruses

Several studies have found evidence of herpesvirus reactivation (particularly Epstein-Barr virus) in Long COVID patients. Small trials of antiviral agents targeting EBV (valacyclovir) have shown promising results in some patients, particularly those with fatigue and cognitive symptoms. Larger controlled trials are ongoing.

Immunomodulatory Approaches

Low-Dose Naltrexone (LDN)

LDN has emerged as one of the most widely used off-label treatments for Long COVID, ME/CFS, and fibromyalgia. At doses of 1.5–4.5mg (far below the standard 50mg dose used for addiction), naltrexone is thought to modulate microglial activation and reduce neuroinflammation.

Several small trials and observational studies have shown improvements in fatigue, pain, and cognitive function in Long COVID patients. A larger randomized controlled trial is underway. LDN is generally well-tolerated, inexpensive, and widely available through compounding pharmacies.

Baricitinib (JAK Inhibitor)

Baricitinib, a JAK1/JAK2 inhibitor used in rheumatoid arthritis, was tested in the RECOVER-VITAL trial for Long COVID. Early results suggested possible benefit in some symptom domains, particularly fatigue and cognitive symptoms, in patients with evidence of ongoing immune activation. Larger trials are ongoing.

IVIG (Intravenous Immunoglobulin)

IVIG has been used off-label in Long COVID patients with evidence of autoantibodies or immune dysregulation. Case series and small trials have shown improvements in some patients, particularly those with small fiber neuropathy or autonomic dysfunction. IVIG is expensive and not widely available for Long COVID outside of specialist centers, but it represents an important option for patients with specific immune profiles.

Autonomic Nervous System Approaches

For Long COVID patients with prominent dysautonomia (POTS, orthostatic intolerance), the treatment approach mirrors that used for primary POTS:

• Increased fluid and sodium intake (2–3 liters of water and 3–5g of sodium daily)
• Compression garments (waist-high, 20–30 mmHg)
• Recumbent exercise (rowing, swimming, recumbent cycling — avoiding upright exercise initially)
• Beta-blockers (propranolol, metoprolol) for heart rate control
• Ivabradine for heart rate reduction without blood pressure effects
• Fludrocortisone for blood volume expansion
• Midodrine for blood pressure support

The RECOVER-AUTONOMIC trial is specifically testing autonomic rehabilitation protocols in Long COVID patients with dysautonomia.

Microbiome and Metabolic Approaches

Probiotics

Several studies have found significant gut microbiome dysbiosis in Long COVID patients, with reductions in beneficial bacteria and increases in inflammatory species. Small trials of specific probiotic formulations have shown improvements in fatigue and gastrointestinal symptoms. The SIM01 probiotic formulation showed promising results in a Hong Kong trial.

Metformin

A large pragmatic trial (COVID-OUT) found that metformin, taken during acute COVID infection, reduced the risk of developing Long COVID by approximately 41%. This finding has generated significant interest in metformin as both a preventive and potentially therapeutic agent for Long COVID. Trials of metformin in established Long COVID are ongoing.

What Patients Can Do Now

Given the current state of evidence, the most evidence-informed approach for Long COVID patients is:

1. Identify your dominant symptom cluster (autonomic, fatigue/PEM, cognitive, pain, immune) and seek treatment targeted to that cluster.
2. Treat dysautonomia aggressively if present — this is the area with the most established treatment protocols.
3. Discuss LDN with your doctor if fatigue and cognitive symptoms are prominent — the risk-benefit ratio is favorable and the evidence is promising.
4. Pace carefully — post-exertional malaise is present in a significant proportion of Long COVID patients, and pushing through fatigue reliably worsens outcomes.
5. Enroll in a clinical trial if possible — trials.gov lists ongoing Long COVID trials by location and symptom type.

The field is moving rapidly. What is considered experimental today may be standard of care within two years. Staying connected to the research — and to a clinician who follows it — is one of the most important things a Long COVID patient can do.